12 Health Care Stocks Moving In Monday's Intraday Session

Benzinga · 3d ago
Gainers
- Impact BioMedical (AMEX:IBO) stock moved upwards by 339.0% to $1.59 during Monday's regular session. The company's market cap stands at $4.3 million.
- Cidara Therapeutics (NASDAQ:CDTX) stock rose 100.14% to $42.07. The market value of their outstanding shares is at $272.6 million.
- Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 85.17% to $0.5. The company's market cap stands at $4.3 million.
- Liminatus Pharma (NASDAQ:LIMN) stock rose 42.23% to $20.52. The company's market cap stands at $375.3 million.
- Skye Bioscience (NASDAQ:SKYE) stock increased by 31.24% to $2.83. The company's market cap stands at $66.9 million.
- Vor Biopharma (NASDAQ:VOR) shares increased by 31.08% to $0.32. The company's market cap stands at $30.0 million.
Losers
- Compass Pathways (NASDAQ:CMPS) shares decreased by 46.8% to $2.46 during Monday's regular session. The market value of their outstanding shares is at $433.1 million.
- Hims & Hers Health (NYSE:HIMS) shares decreased by 33.13% to $42.95. The market value of their outstanding shares is at $14.3 billion.
- Quantum BioPharma (NASDAQ:QNTM) shares decreased by 32.99% to $23.45. The company's market cap stands at $101.7 million.
- Innovative Eyewear (NASDAQ:LUCY) stock declined by 29.86% to $2.48. The company's market cap stands at $10.9 million.
- Regencell Bioscience (NASDAQ:RGC) shares decreased by 29.68% to $26.73. The company's market cap stands at $494.6 million.
- Windtree Therapeutics (NASDAQ:WINT) stock fell 27.35% to $0.41. The company's market cap stands at $2.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.